About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cymbalta Gets Approval for Use in Europe

by Savitha C Muppala on August 23, 2008 at 7:07 PM
Font : A-A+

 Cymbalta Gets Approval for Use in Europe

Cymbalta, the drug manufactured by Eli Lilly is now legally approved to be marketed in Europe.

The drug is used as treatment for generalized anxiety disorder where the victim experiences a great deal of worry and anxiety. Anxiety disorder is known to afflict 9 million people in Europe.

Advertisement

The drug had earlier been approved for use to alleviate severe depressive disorder and neuropathic pain.

For instance, in the United States, the drug was used to treat anxiety diabetic nerve pain, major depressive disorder and fibromyalgia.

Sales for this drug had touched $2.1 billion in 2007. Shares of Eli Lilly has shown progress, up by 1.7%.



Source: Medindia
SAV
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Agoraphobia
Agoraphobia is an anxiety disorder characterised by the patient avoiding spaces, crowds, or ......
Circadian Rhythm Sleep Disorders
Circadian rhythm (also known as sleep/wake cycle or the body clock) is a biological process that ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use